# Novel Myofunctional Therapy Water Bottle to Reduce Obstructive Sleep Apnea and Snoring

> **NIH NIH R43** · REMASTERED SLEEP LLC · 2022 · $293,675

## Abstract

Project Summary: There is a clear unmet need to provide alternative, first-line solutions for both obstructive
sleep apnea (OSA) and primary snoring. Most people suffering from OSA are currently not receiving treatment
with estimates of 80% undiagnosed (23 million Americans) and 40% non-adherence to the gold standard
treatment, continuous positive air pressure among diagnosed patients. This has serious implications for overall
health resulting in increased daytime sleepiness and comorbidities of hypertension, heart disease, diabetes,
and depression. The undiagnosed population alone contributes to an estimated cost burden of $30 billion from
comorbidities and mental health, $26.2 billion from motor vehicle accidents, $6.5 billion from workplace
accidents, and $86.9 billion from lost productivity, with a total cost burden to the US of $149.6 billion per year
[1]. Although most people are undiagnosed, indicators such as snoring can be found in up to 94% of OSA
patients [2] and habitual snorers (snoring ≥ 3 nights/week) with bed partners often seek treatment for their
snoring. Low risk, low burden, and affordable solutions that can be easily administered to OSA patients and
primary snorers open new treatment paradigms to reduce the risk of OSA and snoring. Oropharyngeal
exercises are a promising therapy for motivated patients and have shown, on average, to reduce apnea
hypopnea index (AHI) by 14.3 points and snoring by more than 50% [3,4]. Despite their efficacy, a major
obstacle to patient adoption and adherence exists that demands delivery of therapy in less burdensome ways.
In this SBIR Phase I project, REMastered Sleep will characterize, develop, and clinically test a simplified
myofunctional therapy nozzle and reusable water bottle to improve adoption and adherence of oropharyngeal
exercises. The simplified exercise regimen and connection of the therapy with the biologically driven action of
drinking water greatly reduces daily therapy burden, which will lead to improved patient adherence and
adoption. The specific aims are: Aim 1: Characterize, develop, and test pre-production devices. Key therapy
design features of the myofunctional therapy nozzle will be characterized. The device will be developed and
tested to well-defined specifications. The preproduction models will use production grade silicone materials to
meet pre-established design and safety requirements. Aim 2: Conduct feasibility study in human subjects. A
randomized, non-significant risk device study will be conducted to assess adherence and quality of life after
two months use of the MT nozzle water bottle vs. control for mild to moderate OSA patients. Secondary
outcome measures will compare changes in myofunctional assessment, AHI, oxygen saturation (SpO2), and
snoring intensity/percentage. Phase I will de-risk the therapy and device and provide input for a future Phase II
proposal that will focus on further optimization of the therapy and conducting a larger more inclusive clini...

## Key facts

- **NIH application ID:** 10385206
- **Project number:** 1R43HL160368-01A1
- **Recipient organization:** REMASTERED SLEEP LLC
- **Principal Investigator:** Anders Olmanson
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $293,675
- **Award type:** 1
- **Project period:** 2022-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10385206

## Citation

> US National Institutes of Health, RePORTER application 10385206, Novel Myofunctional Therapy Water Bottle to Reduce Obstructive Sleep Apnea and Snoring (1R43HL160368-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10385206. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*